It is under accumulation with uptrend back to $8+ support area.
A sharp breakout likely when Entyce drug is launched early 2017. Big catalyst. I expect 1q17 cc to be pivotal for the company unless they ink another deal with Elanco or someone else before than.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.